Company to also Present at Stanford Group 13th Annual Healthcare Conference
SAN DIEGO, Jan. 15 /PRNewswire-FirstCall/ -- CryoCor, Inc. (Nasdaq: CRYO), a medical device company focused on the treatment of cardiac arrhythmias, announced today that it will showcase its Cardiac Cryoablation System and its next generation ablation catheter, Quantum, at the Boston Atrial Fibrillation Symposium, January 17-19, 2008. CryoCor's products will be located at Booth 801.
In August 2007, the FDA approved the Cryoablation System for the treatment of right atrial flutter and CryoCor completed enrollment of its pivotal clinical study of the System for the treatment of atrial fibrillation. The Company has completed animal studies with Quantum, which is designed to significantly reduce the required time for an atrial fibrillation catheter ablation. CryoCor expects to enter human trials with Quantum in the second quarter of 2008.
Ed Brennan, Ph.D., President and Chief Executive Officer of CryoCor, said, "The Boston AF Symposium is the premier industry event focused on the treatment of atrial fibrillation, and as such, offers a tremendous forum to showcase our products to potential users. We look forward to the opportunity to increase the knowledge of our Cryoablation System and the unique advantages our technology provides physicians."
The Company also announced that Edward F. Brennan, President and Chief Executive Officer, and Gregory J. Tibbitts, Chief Financial Officer, are scheduled to present at the Stanford Group 13th Annual Healthcare Conference in Washington, D.C. on Thursday, January 17, 2008 at 7:45 a.m. ET at The Four Seasons Hotel.
A live Web cast and recording of the presentation will be available online from the investor relations page of the Company's corporate Web site at http://www.cryocor.com. The recording will remain available on CryoCor's Web site for at least 30 days following presentation.
CryoCor is a medical technology company that has developed and manufactures a disposable catheter system based on its proprietary cryoablation technology for the minimally invasive treatment of cardiac arrhythmias. The Company's product, the CryoCor Cardiac Cryoablation System, or the Cryoablation System, is designed to treat cardiac arrhythmias through the use of cryoenergy, or extreme cold, to destroy targeted cardiac tissue. The Cryoablation System has been approved in Europe for the treatment of atrial fibrillation, and atrial flutter, the two most common and difficult to treat arrhythmias, since 2002. In the United States, CryoCor is conducting a pivotal trial to evaluate the safety and efficacy of the Cryoablation System for the treatment of atrial fibrillation and the Cryoablation System has been approved for the treatment of right atrial flutter. For more information please visit the Company's website at http://www.cryocor.com
Forward Looking Statements
The statements in this press release that are not descriptions of
historical facts are forward-looking statements that are subject to risks
and uncertainties. These include statements related to the advantages and
benefits provided by the Company's technology and the timing for when the
Company expects to enter human trials with Quantum. Such statements are
only predictions and reflect CryoCor's expectations and assumptions as of
the date of this press release based on currently available operating,
financial, and competitive information. The actual events or results may
differ materially from those projected in such forward-looking statements
due to a number of factors, including risks involved with CryoCor's
technology, its development and the Company's anticipated timetable for
developing and evaluating its technology; risks involved with the diagnosis
and treatment of atrial arrhythmias; risks associated with the Company's
dependence on patents and proprietary rights; risks associated with the
Company's protection and enforcement of its patents and proprietary rights;
risks associated with the development or availability of competitive
products or technologies; risks associated with the Company's ability to
maintain and achieve milestones under collaborative agreements and the
other risks and uncertainties identified in the Company's filings with the
Securities and Exchange Commission. These forward-looking statements speak
only as of the date hereof. The Company expressly disclaims any intent or
obligation to update any of these forward- looking statements.
Gregory J. Tibbitts
Chief Financial Officer
The Ruth Group
Nick Laudico / Zack Kubow (investors)
(646) 536-7030 / 7020
Jason Rando (media)
|SOURCE CryoCor, Inc.|
Copyright©2008 PR Newswire.
All rights reserved